FDA approves Keytruda (pembolizimab) for
- This topic has 2 replies, 1 voice, and was last updated 7 years, 7 months ago by
.
Viewing 3 posts - 1 through 3 (of 3 total)
-
Posts
-
A more detailed information provided by the FDA
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm
Please know that MSI is a DNA repair gene and is indicative of Lynch Syndrome, which can lead to a variety of cancer manly colon, but also cholangiocarcinoma.
Most physicians have tissue tested for MSI.
Hugs
Marionpatients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options
Read more:
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
Viewing 3 posts - 1 through 3 (of 3 total)
- The forum ‘New Developments’ is closed to new topics and replies.